Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 32 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Phase 3Results posted
• Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckTerminatedNCT03854032Phase 2Results posted
• Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast CancerCompletedNCT03853707Phase 1/2Results posted
• AMG 404 in Patients With Advanced Solid TumorsCompletedNCT03853109Phase 1Results posted
• Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension StudyCompletedNCT03850444Phase 3Results posted
• Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03848845Phase 1/2Results posted
• Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic MetastasesTerminatedNCT03844750Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedNCT03834519Phase 3Results posted
• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)CompletedNCT03834506Phase 3Results posted
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)TerminatedNCT03834493Phase 3Results posted
• Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)TerminatedNCT03833427Phase 1Results posted
• Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)TerminatedNCT03833167Phase 3Results posted
• Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)CompletedNCT03830866Phase 3Results posted
• Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell CarcinomaCompletedNCT03829969Phase 3Results posted
• Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerCompletedNCT03829722Phase 2Results posted
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
• Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatTerminatedNCT03823131Phase 2Results posted
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2Results posted
• Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results posted
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
• VAccination in Early and ADvanced Prostate caNCErTerminatedNCT03815942Phase 1/2Results posted
• Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC PatientsCompletedNCT03812549Phase 1Results posted
• Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)Active, not recruitingNCT03811002Phase 3Results posted
• A Study of Olaparib and Durvalumab in Prostate CancerTerminatedNCT03810105Phase 2Results posted
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03805594Phase 1Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03800836Phase 1Results posted
• Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerCompletedNCT03800602Phase 2Results posted
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results posted
• Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedNCT03794544Phase 2Results posted
• Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of EsophagusCompletedNCT03792347Phase 1Results posted
• NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results posted
• Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cARTTerminatedNCT03787095Phase 1/2Results posted
• A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerCompletedNCT03785925Phase 2Results posted
• Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerCompletedNCT03785873Phase 1/2Results posted
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results posted
• Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal AdenocarcinomasCompletedNCT03783936Phase 2Results posted
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Phase 3Results posted
• Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)CompletedNCT03783078Phase 3Results posted
• Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaTerminatedNCT03782064Phase 2Results posted
• Abemaciclib and Nivolumab for Subjects With Hepatocellular CarcinomaTerminatedNCT03781960Phase 2Results posted
• This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedNCT03780725Phase 1Results posted
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03777657Phase 3Results posted
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results posted
• Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPCTerminatedNCT03770455Phase 2Results posted
• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)TerminatedNCT03769467Phase 1/2Results posted
• A Study of Isatuximab-based Therapy in Participants With LymphomaTerminatedNCT03769181Phase 1/2Results posted
• Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.CompletedNCT03767582Phase 1/2Results posted
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)Active, not recruitingNCT03765918Phase 3Results posted
• An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaCompletedNCT03765229Phase 2Results posted
• A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Phase 3Results posted
• BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural MesotheliomaCompletedNCT03762018Phase 3Results posted
• Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedNCT03761914Phase 1/2Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results posted
• Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialTerminatedNCT03753919Phase 2Results posted
• IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)CompletedNCT03753659Phase 2Results posted
• Trial of Pembrolizumab in Cancer of Unknown PrimaryCompletedNCT03752333Phase 2Results posted
• A Study of LY3415244 in Participants With Advanced Solid TumorsTerminatedNCT03752177Phase 1Results posted
• Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersCompletedNCT03749460Phase 1/2Results posted
• Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell CancerTerminatedNCT03747484Phase 1/2Results posted
• Avelumab and Radiation in Muscle-Invasive Bladder CancerTerminatedNCT03747419Phase 2Results posted
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Active, not recruitingNCT03747120Phase 2Results posted
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Phase 3Results posted
• Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid TumorsCompletedNCT03744468Phase 1/2Results posted
• Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingCompletedNCT03743766Phase 2Results posted
• Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)CompletedNCT03740165Phase 3Results posted
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedNCT03739710Phase 2Results posted
• Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03739619Phase 1/2Results posted
• Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical CancerCompletedNCT03738228Phase 1Results posted
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsActive, not recruitingNCT03737643Phase 3Results posted
• Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaTerminatedNCT03737123Phase 2Results posted
• A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03735121Phase 3Results posted
• NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal CancerActive, not recruitingNCT03734809Phase 2Results posted
• Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerActive, not recruitingNCT03734692Phase 1/2Results posted
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive, not recruitingNCT03732677Phase 3Results posted
• A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)CompletedNCT03730012Phase 1/2Results posted
• A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT03729245Phase 3Results posted
• Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeActive, not recruitingNCT03728972Phase 2Results posted
• Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaCompletedNCT03727880Phase 2Results posted
• A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerCompletedNCT03726879Phase 3Results posted
• Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionTerminatedNCT03724968Phase 2Results posted
• Study of Avelumab-M3814 CombinationsCompletedNCT03724890Phase 1Results posted
• Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerTerminatedNCT03723915Phase 2Results posted
• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeActive, not recruitingNCT03718767Phase 2Results posted
• Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCCompletedNCT03717155Phase 2Results posted
• Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx CancerCompletedNCT03715946Phase 2Results posted
• Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)CompletedNCT03715205Phase 4Results posted
• Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03713944Phase 2Results posted
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Phase 3Results posted
• A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue SarcomaTerminatedNCT03711279Phase 2Results posted
• Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerCompletedNCT03711058Phase 1/2Results posted
• Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With PembrolizumabTerminatedNCT03709706Phase 1/2Results posted
• A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsCompletedNCT03708328Phase 1Results posted
• A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsActive, not recruitingNCT03706690Phase 3Results posted
• Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian CancerCompletedNCT03704467Phase 1Results posted
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results posted

← Immune Checkpoint Inhibitors overview